More trouble ahead; is gene therapy coming of age?

Bibliography

• Wilson JM. Adverse events in gene transfer trials and an agenda for the new year. Hum Gene Ther 2008;19(1):1-2
   PubMed Web of Science ®Google Scholar
• Kaiser J. No easy answers in gene therapy death. ScienceNOW Daily News, 2007. Available from: http://sciencenow.sciencemag.org/cgi/content/full/2007/917/1 [Last accessed 21 February 2008]
   Google Scholar
• Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24(3):257-61
   PubMed Web of Science ®Google Scholar
• Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001;4(6):586-92
   PubMed Web of Science ®Google Scholar
• Flotte TR, Conlon TJ, Poirier A, et al. Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum Gene Ther 2007;18(3):245-56
   PubMed Web of Science ®Google Scholar
• Couzin J, Kaiser J. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science 2005;307(5712):1028
   PubMed Web of Science ®Google Scholar
• Carmen IH. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 2001;3(4):425-8
   PubMed Web of Science ®Google Scholar
• Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 1986;46(4 Pt 2):2101-4
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Chapman PB, Wong G, et al. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res 1990;50(23):7490-5
   PubMed Web of Science ®Google Scholar
• Stewart JA, Belinson JL, Moore AL, et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990;50(19):6302-10
   PubMed Web of Science ®Google Scholar
• Wang Y, Hallden G, Hill R, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003;21(11):1328-35
   PubMed Web of Science ®Google Scholar
• Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6(10):1134-9
   PubMed Web of Science ®Google Scholar
• Jia H. Gene therapy finds welcoming environment in China. Nat Med 2006;12(3):263-4
   PubMed Web of Science ®Google Scholar
• HVTN050. HIV Vaccine Trial Network: November 2007 HVTN Conference Presentations. Available from: http://www.hvtn.org/science/1107.html [Last accessed 21 February 2008]
   Google Scholar
• Rogers S. Reflections on issues posed by recombinant DNA molecule technology. II. In: Lappe M, Morison RS, editors, Ethical and scientific issues posed by human uses of molecular genetics. New York: New York Academy of Science; 1976. p. 66-70
   Google Scholar
• Recombinant DNA and gene transfer: Office of Biotechnology Activities. Available from: http://www4.od.nih.gov/oba/Rdna.htm [Last accessed 21 February 2008]
   Google Scholar
• Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 1995;270(5235):475-80
   PubMed Web of Science ®Google Scholar
• Fraites TJ Jr, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002;5(5 Pt 1):571-8
   PubMed Web of Science ®Google Scholar
• Roth DA, Tawa NE Jr, O'Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001;344(23):1735-42
   PubMed Web of Science ®Google Scholar
• Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007;117(8):2083-6
   PubMed Web of Science ®Google Scholar
• Board of the European Society of Gene and Cell Therapy Ecotcnoe, Executive of the Consert Integrated Project. Case of Leukaemia Associated with X-Linked Severe Combined Immunodeficiency Gene Therapy Trial in London. Hum Gene Ther 2008;19(1):3-4
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348(3):255-6
   PubMed Web of Science ®Google Scholar
• Woods NB, Bottero V, Schmidt M, et al. Gene therapy: therapeutic gene causing lymphoma. Nature 2006;440(7088):1123
   PubMed Web of Science ®Google Scholar
• Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007;117(8):2233-40
   PubMed Web of Science ®Google Scholar
• Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 2003;9(4):367-9
   PubMed Web of Science ®Google Scholar
• Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 2006;103(5):1457-62
   PubMed Web of Science ®Google Scholar
• Tan PH, Xue SA, Wei B, et al. Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design. Mol Med 2007;13(3-4):216-26
   PubMed Web of Science ®Google Scholar
• Manno CS, Arruda VR, Pierce GF, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
   PubMed Web of Science ®Google Scholar
• Manno CS, Arruda VR, Pierce GF, et al. CORRIGENDUM: Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(5):592
   Web of Science ®Google Scholar
• Annoni A, Battaglia M, Follenzi A, et al. The immune response to lentiviral-delivered transgene is modulated in vivo by transgene expressing antigen presenting cells but not by CD4+CD25+ regulatory T cells. Blood 2007
   Google Scholar
• Tan PH, Beutelspacher SC, Xue SA, et al. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood 2005;105(10):3824-32
   PubMed Web of Science ®Google Scholar
• Tan PH, Xue SA, Manunta M, et al. Effect of vectors on human endothelial cell signal transduction: implications for cardiovascular gene therapy. Arterioscler Thromb Vasc Biol 2006;26(3):462-7
   PubMed Web of Science ®Google Scholar
• Dewey RA, Morrissey G, Cowsill CM, et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999;5(11):1256-63
   PubMed Web of Science ®Google Scholar
• Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006;12(5):1599-605
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Estimates of Funding for Various Diseases, Conditions, Research Areas. Available from: http://www.nih.gov/news/fundingresearchareas.htm [Last accessed 21 February 2008]
   Google Scholar
• Silber TJ. Human gene therapy, consent, and the realities of clinical research: is it time for a research subject advocate? Hum Gene Ther 2008;19(1):9-10
   PubMed Web of Science ®Google Scholar
• Caplan AL. If it's broken, shouldn't it be fixed? Informed consent and initial clinical trials of gene therapy. Hum Gene Ther 2008;19(1):5-6
   PubMed Web of Science ®Google Scholar
• Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006;24(6):687-96
   PubMed Web of Science ®Google Scholar
• Tan PH, Sagoo P, Chan C, et al. Inhibition of NF-κB and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. J Immunol 2005;174(12):7633-44
   PubMed Web of Science ®Google Scholar
• Tan PH, Beutelspacher SC, Wang YH, et al. Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther 2005;11(5):790-800
   PubMed Web of Science ®Google Scholar
• Tan PH, Yates JB, Xue SA, et al. Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood 2005;106(9):2936-43
   PubMed Web of Science ®Google Scholar
• Li S, Wu SP, Whitmore M, et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 1999;276(5 Pt 1):L796-804
   PubMed Web of Science ®Google Scholar
• Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999;10(11):1773-81
   PubMed Web of Science ®Google Scholar
• Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993;90(18):8392-6
   PubMed Web of Science ®Google Scholar
• Felgner PL, Ringold GM. Cationic liposome-mediated transfection. Nature 1989;337(6205):387-8
   PubMed Web of Science ®Google Scholar
• Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999;96(22):12816-21
   PubMed Web of Science ®Google Scholar
• Theoharis S, Manunta M, Tan PH. Gene delivery to vascular endothelium using chemical vectors: implications for cardiovascular gene therapy. Expert Opin Biol Ther 2007;7(5):627-43
   PubMed Web of Science ®Google Scholar
• Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354(9189):1493-8
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374(6522):546-9
   PubMed Web of Science ®Google Scholar
• Tan Y, Li S, Pitt BR, Huang L. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999;10(13):2153-61
   PubMed Web of Science ®Google Scholar
• Tan PH, Tan PL, George AJ, Chan CL. Gene therapy for transplantation with viral vectors – how much of the promise has been realized? Expert Opin Biol Ther 2006;6(8):759-72
   PubMed Web of Science ®Google Scholar
• Lieber A, Kay MA, Li ZY. Nuclear import of moloney murine leukemia virus DNA mediated by adenovirus preterminal protein is not sufficient for efficient retroviral transduction in nondividing cells. J Virol 2000;74(2):721-34
   PubMed Web of Science ®Google Scholar